At a glance
Summary
Revvity delivered one of the stronger Healthcare weeks, rising 13.0% on 1.5x normal volume and lifting its 12-week return to 27.2%. The close sits 15.7% above the weekly Trend Line and 8.7% above Sharemaestro Fair Value, showing firm demand near the upper end of the yearly range. The caution is that the weekly Trend Signal is still inactive, activity pressure is positive but not broad enough for a fresh buy reading, and the Expectancy Model remains negative at 41.52%.
- RVTY closed at $113.0 for the week ended 26 June, up 13.0%, with volume of 9.9M shares versus a 13-week average of 6.6M.
- The stock is 4.4% below its 52-week high of $118.2 and sits at 86.0% of its one-year range, a constructive but more demanding position.
- Price is 15.7% above the weekly Trend Line at $97.66 and 8.7% above Sharemaestro Fair Value at $103.9, reflecting premium demand.
- Market Dynamics are mixed: activity pressure is positive at 0.87 and relative strength has improved to 9.41, but the Trend Signal remains inactive and expectancy is negative.
- Healthcare breadth is uneven, with only 37.0% active Trend breadth, while Diagnostics & Research shows stronger activity pressure at 77.1% but weaker relative-strength breadth at 33.3%.
Company analysis
The move in context
Weekly move draws participation, but the signal is not fully aligned
Revvity’s 13.0% weekly gain was backed by 9.9M shares, about 1.5x both its 13-week and 52-week volume averages. That gives the move more weight than a low-turnover rebound, especially after the stock had spent the prior three weeks moving from $98.37 to $100.0 before the latest jump to $113.0. The four-week return is now 8.1%, while the 12-week return stands at 27.2%, confirming a sharp quarterly recovery in the Waltham-based diagnostics and life-sciences tools name.
The price position is strong but less forgiving. RVTY is now 15.7% above its weekly Trend Line of $97.66 and 8.7% above Sharemaestro Fair Value of $103.9. It is also only 4.4% below the 52-week high of $118.2, with the latest close in the top fifth of the annual range. That combination supports the opportunity evidence, but it also raises the bar for follow-through because the setup is no longer coming from a discounted area.
Healthcare context helps, though breadth is selective
Within US Healthcare, Revvity’s weekly return ranked in the stronger part of the group, with the sector averaging a 5.2% one-week gain and 9.0% over 12 weeks. The stock’s relative rank among US Healthcare peers sits around the 84th percentile, helped by positive Market Dynamics and relative strength. Still, sector confirmation is incomplete: only 37.0% of Healthcare constituents show active weekly trend signals, while positive relative-strength breadth is 44.0%.
The industry read is more supportive on participation but still narrow on trend. US Diagnostics & Research averaged a 7.4% weekly gain and 15.7% over 12 weeks, both below RVTY’s latest pace, and activity-pressure breadth in the industry is high at 77.1%. The weaker point is that only 31.2% of the industry has active weekly Trend Signals and just 33.3% shows positive relative strength. Peers such as Twist Bioscience, Biodesix and NeoGenomics posted much larger multi-week advances, so Revvity’s move is improving rather than dominating the group.
Momentum has improved, but risk evidence keeps the read balanced
Sharemaestro’s signal state is deliberately mixed. Activity pressure is positive at 0.87 and relative leadership is positive at 9.41 after a sharp four-week improvement, while price is comfortably above the Trend Line. Against that, the Trend backdrop remains inactive, there is no fresh activity-pressure buy reading, and the Expectancy Model is negative at 41.52%. The composite score of 58 fits that balanced read: constructive price action, incomplete regime confirmation.
Risk is not excessive, but it is active. Thirteen-week volatility is 7.0%, above the 52-week level of 6.2%, and the 52-week split is 28 upside weeks versus 24 downside weeks. Average winning weeks of 5.2% are only slightly larger than average losing weeks of 5.0%, while sharp gains and sharp losses each account for 30.8% of recent weekly outcomes. The next test is whether RVTY can absorb its range-top position with volume still above 1.5x, or whether the move stalls near the old high before the Trend Signal confirms.
What to watch next
The immediate market question is whether Revvity can press through the remaining 4.4% gap to its 52-week high without activity pressure fading. A close that holds well above the $103.9 Fair Value area would preserve the premium-demand argument, while a retreat back towards the Trend Line at $97.66 would weaken the recovery profile.
Volume matters in the next leg. The latest 9.9M-share week gave the rebound credible participation, but another above-average week would be stronger evidence that institutions are still adding exposure. If volume cools while price tests the high, the risk shifts towards exhaustion rather than continuation.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line37.0%
Positive Relative Strength44.0%
US Diagnostics & Research
48 tracked companiesAbove Trend Line31.3%
Positive Relative Strength33.3%
Balanced view
What supports the case, and what could weaken it
What is working
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
What needs caution
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- The Expectancy Model is negative at 41.52%, which weighs against the setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/rvty-13-percent-volume-trend-signal-inactive/.
Follow new Sharemaestro research through the RSS feed or JSON feed.